|Major adverse events∗||29 (5.8)|
|Pericardial effusion||33 (6.6)|
|Serious pericardial effusion†||16 (3.2)|
|Bailout cardiovascular surgery||5 (1.0)|
|Bailout transcatheter intervention||10 (2.0)|
|Cardiopulmonary resuscitation||7 (1.4)|
|Vascular access complication related to LAAC|
|Vascular access complication unrelated to LAAC||8 (1.6)|
|Bleeding related to LAAC|
|Bleeding unrelated to LAAC||8 (1.6)|
|Device embolization||10 (2.0)|
|Air embolization not resulting in stroke||3 (0.6)|
Values are n (%). Note that adverse events were not mutually exclusive; more than 1 event occurred in several individual patients.
LAAC = left atrial appendage closure.
↵∗ Composite of death, stroke, Valve Academic Research Consortium major or life-threatening bleeding, major access-vessel complication, device embolization, need for cardiovascular surgery, cardiopulmonary resuscitation, and serious pericardial effusion.
↵† Hemodynamically significant pericardial effusion requiring drainage or prolonging hospitalization.